Diagnostic performance of ⁶⁸Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

ABSTRACT:

Purpose

Since the clinical introduction of ⁶⁸Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.

Methods

We performed a retrospective analysis of 1007 consecutive patients who were scanned with ⁶⁸Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease. Patients with untreated primary PCa or patients referred for PSMA radioligand therapy were excluded. The possible effects of different variables including PSA level and PSA doubling time (PSA_DT), PSA velocit

SUBMITTER: Afshar-Oromieh A 

PROVIDER: S-EPMC5486817 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature